Skip to main content
Canna~Fangled Abstracts

Cannabinoid-Based Medicines and Multiple Sclerosis

By December 17, 2020No Comments
. 2021;1264:111-129.

doi: 10.1007/978-3-030-57369-0_8.

Clementina Manera 1, Simone Bertini 2
Affiliations 

Abstract

The emerging role of the endocannabinoid system (ECS) in the control of symptoms and disease progression in multiple sclerosis (MS) has been highlighted by recent studies. MS is a chronic, immune-mediated, and demyelinating disorder of the central nervous system with no cure so far. It is widely reported that cannabinoids might be used to control MS symptoms and that they also might exert neuroprotective effects and slow down disease progression. The aim of this chapter is to give an overview of the main endogenous and synthetic cannabinoids used for the symptomatic amelioration of MS and their beneficial outcomes, providing new possible perspectives for the treatment of this disease.

 

Keywords: Arachidonoylethanolamine (AEA) reuptake inhibitors, Cannabinoid receptors, Endocannabinoid system, Fatty acid amide hydrolase (FAAH) inhibitors, Monoacylglycerol lipase (MAGL) inhibitors, Multiple sclerosis

References

    1. Alberti TB, Barbosa WL, Vieira JL et al (2017) (−)-β-Caryophyllene, a CB2 receptor-selective Phytocannabinoid, suppresses motor paralysis and Neuroinflammation in a murine model of multiple sclerosis. Int J Mol Sci 18:691 – PMC – DOI – PubMed
    1. Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators trends. Pharmacol Sci 35:284–292
    1. Andrzejewski K, Barbano R, Mink J (2016) Cannabinoids in the treatment of movement disorders: a systematic review of case series and clinical trials. Basal Ganglia 6:73–181 – DOI
    1. Arevalo-Martin A, Vela JM, Molina-Holgado E et al (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23:2511–2516 – PubMed – PMC – DOI
    1. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467–479 – PubMed – PMC – DOI

Leave a Reply